SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-078226
Filing Date
2024-03-27
Accepted
2024-03-27 07:31:01
Documents
13
Period of Report
2024-03-21
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d797057d8k.htm   iXBRL 8-K 27590
  Complete submission text file 0001193125-24-078226.txt   151061

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA grtx-20240321.xsd EX-101.SCH 2854
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20240321_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20240321_pre.xml EX-101.PRE 11261
16 EXTRACTED XBRL INSTANCE DOCUMENT d797057d8k_htm.xml XML 3632
Mailing Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355
Business Address 45 LIBERTY BLVD. SUITE 230 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

IRS No.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 24785791
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)